Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Publication
, Journal Article
Fong, Y; Dang, L; Zhang, B; Fintzi, J; Chen, S; Wang, J; Rouphael, NG; Branche, AR; Diemert, DJ; Falsey, AR; Losada, C; Baden, LR; Frey, SE ...
Published in: Clin Infect Dis
September 26, 2024
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
September 26, 2024
Location
United States
Related Subject Headings
- Microbiology
- 3202 Clinical sciences
- 11 Medical and Health Sciences
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Fong, Y., Dang, L., Zhang, B., Fintzi, J., Chen, S., Wang, J., … Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. (2024). Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. https://doi.org/10.1093/cid/ciae465
Fong, Youyi, Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen, Jing Wang, Nadine G. Rouphael, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.” Clin Infect Dis, September 26, 2024. https://doi.org/10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2024 Sep 26;
Fong, Youyi, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.” Clin Infect Dis, Sept. 2024. Pubmed, doi:10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2024 Sep 26;
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
September 26, 2024
Location
United States
Related Subject Headings
- Microbiology
- 3202 Clinical sciences
- 11 Medical and Health Sciences
- 06 Biological Sciences